Investigational Drug Information for Lucitanib
✉ Email this page to a colleague
What is the drug development status for Lucitanib?
Lucitanib is an investigational drug.
There have been 9 clinical trials for Lucitanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Bristol-Myers Squibb.
There are forty-two US patents protecting this investigational drug and four hundred and two international patents.
Summary for Lucitanib
| US Patents | 42 |
| International Patents | 402 |
| US Patent Applications | 179 |
| WIPO Patent Applications | 140 |
| Japanese Patent Applications | 47 |
| Clinical Trial Progress | Phase 2 (2019-11-14) |
| Vendors | 45 |
Recent Clinical Trials for Lucitanib
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Clovis Oncology, Inc. | Phase 1/Phase 2 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Eli Lilly and Company | Phase 1/Phase 2 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Exelixis | Phase 1/Phase 2 |
Clinical Trial Summary for Lucitanib
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
US Patents for Lucitanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lucitanib | ⤷ Sign Up | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Lucitanib | ⤷ Sign Up | Human anti-VEGFR-2/KDR antibodies | KADMON CORPORATION, LLC (New York, NY) | ⤷ Sign Up |
| Lucitanib | ⤷ Sign Up | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Lucitanib | ⤷ Sign Up | Rho kinase inhibitors | KADMON CORPORATION, LLC (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lucitanib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lucitanib | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Sign Up |
| Lucitanib | Canada | CA2926386 | 2032-10-05 | ⤷ Sign Up |
| Lucitanib | China | CN105007939 | 2032-10-05 | ⤷ Sign Up |
| Lucitanib | China | CN109160950 | 2032-10-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
